Anti-LAP3 / Leucine aminopeptidase 3, clone 31L65

Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol, 0.4-0.5mg/ml BSA. LAP3 antibody detects leucine aminopeptidase 3, a cytosolic enzyme that catalyzes the removal of N-terminal amino acids, particularly leucine, from peptides. LAP3 is involved in protein degradation, antigen processing, and amino acid recycling. Its activity contributes to maintaining intracellular amino acid pools and supporting protein turnover under normal and stress conditions.Research using LAP3 antibody has linked this enzyme to cancer, autoimmune disease, and metabolic regulation. Elevated LAP3 expression has been reported in various cancers, including hepatocellular carcinoma and breast cancer, where it may promote tumor cell proliferation and invasion. LAP3 has also been implicated in antigen processing for MHC class I presentation, connecting it to immune system regulation. Genetic studies suggest associations between LAP3 variants and autoimmune conditions such as systemic lupus erythematosus.In metabolic contexts, LAP3 participates in amino acid homeostasis and cellular responses to nutrient availability. Dysregulation of aminopeptidases can disrupt nitrogen balance and protein catabolism, influencing cell growth and survival. The dual role of LAP3 in both metabolism and immune regulation makes it an important target for research into cellular adaptation and disease mechanisms.Antibodies against LAP3 are validated for western blot, immunohistochemistry, and immunofluorescence. These reagents allow researchers to assess LAP3 expression in tissues, examine subcellular localization, and evaluate its contribution to immune and metabolic pathways. Clone-based LAP3 antibodies ensure specificity when distinguishing LAP3 from other aminopeptidase family members.NSJ Bioreagents provides this LAP3 antibody for research into cancer biology, immunity, and metabolism.